CoChat

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

Open access
Bergman, R N, Phillips, L S, Cobelli, C · 1981 · Journal of Clinical Investigation

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 3 of the 11 sources its claims cite were checked for support.

Abstract

The quantitative contributions of pancreatic responsiveness and insulin sensitivity to glucose tolerance were measured using the "minimal modeling technique" in 18 lean and obese subjects (88-206% ideal body wt). The individual contributions of insulin secretion and action were measured by interpreting the dynamics of plasma glucose and insulin during the intravenous glucose tolerance test in terms of two mathematical models. One, the insulin kinetics model, yields parameters of first-phase (phi 1) and second-phase (phi 2) responsivity of the beta-cells to glucose. The other glucose kinetics model yields the insulin sensitivity parameters, SI. Lean and obese subjects were subdivided into good (KG greater than 1.5) and lower (KG less than 1.5) glucose tolerance groups. The etiology of lower glucose tolerance was entirely different in lean and obese subjects. Lean, lower tolerance was related to pancreatic insufficiency (phi 2 77% lower than in good tolerance controls [P less than 0.03]), but insulin sensitivity was normal (P greater than 0.5). In contrast, obese lower tolerance was entirely due to insulin resistance (SI diminished 60% [P less than 0.01]); pancreatic responsiveness was not different from lean, good tolerance controls (phi 1: P greater than 0.06; phi 2: P greater than 0.40). Subjects (regardless of weight) could be segregated into good and lower tolerance by the product of second-phase beta-cell responsivity and insulin sensitivity (phi 2 . SI). Thus, these two factors were primarily responsible for overall determination of glucose tolerance. The effect of phi 1 was to modulate the KG value within those groups whose overall tolerance was determined by phi 2 . SI. This phi 1 modulating influence was more pronounced among insulin sensitive (phi 1 vs. KG, r = 0.79) than insulin resistant (obese, low tolerance; phi 1 vs. KG, r = 0.91) subjects. This study demonstrates the feasibility of the minimal model technique to determine the etiology of impaired glucose tolerance.

Overview

CoChat Summary

TL;DR

The paper applies the “minimal modeling” technique to intravenous glucose tolerance tests in 18 lean and obese subjects to quantify insulin sensitivity and β-cell glucose responsiveness. It finds that low glucose tolerance in lean subjects is due mainly to pancreatic insufficiency, whereas in obese subjects it is due mainly to insulin resistance.

Key findings

  • Lean subjects with lower glucose tolerance had a 77% lower second-phase β-cell responsivity (φ2) than lean good-tolerance controls (P < 0.03), while insulin sensitivity was normal (P > 0.5).
  • Obese subjects with lower glucose tolerance had insulin sensitivity diminished by 60% versus lean good-tolerance controls (P < 0.01), with pancreatic responsiveness not significantly different (φ1: P > 0.06; φ2: P > 0.40).
  • The product φ2·S segregated tolerance: good-tolerance subjects averaged 160 ± 26 versus 40 ± 7 for low-tolerance subjects (P < 0.001); a φ2·S threshold of 75 separated 9 of 10 low-tolerance and 7 of 8 good-tolerance subjects.
  • First-phase responsivity (φ1) modulated KG within groups: φ1 vs KG correlated r = 0.79 in insulin-sensitive subjects and r = 0.91 in insulin-resistant obese low-tolerance subjects; glucose effectiveness (P1) was lower in low-tolerance subjects (1.4 ± 0.2 vs. 3.6 ± 0.3 %/min, P < 0.01).

Methods

  • IVGTT was performed in 18 subjects (8 male, 10 female; 88–206% ideal body weight) after an overnight fast, with 300 mg/kg glucose injected over 60 s and frequent plasma glucose and insulin sampling.
  • Two minimal mathematical models were used: a glucose kinetics model to estimate insulin sensitivity (S) and an insulin kinetics model to estimate first-phase (φ1) and second-phase (φ2) β-cell responsivity to glucose.
  • Parameters were estimated by nonlinear least squares with covariance-matrix accuracy assessment; subjects were divided into good tolerance (KG > 1.5) and lower tolerance (KG < 1.5), and comparisons used Student’s t test and regression.

Limitations

  • The paper states that complete validation of the model and optimal input patterns is required before the approach can be proposed as a clinical tool, and that more study of the range of glucose doses over which the model applies would be worthwhile.
  • The authors note that the present studies were limited to testing whether the model and its parameters apply and can be obtained from other doses and stimulus patterns.
  • Evident from the text: the sample is small (n = 18), the tolerance cutoff at KG = 1.5 was arbitrary because no KG values fell between 1.4 and 1.8, and φ1 varied widely within groups, limiting clear segregation by φ1·S.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci110398

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Image 2
From the PDF
FiGURE 2 Frequency histogram of the KG values of the 18 subjects under study, calculated from the IVGTT. Because no KG values were found between 1.4 and 1.8, we arbitrarily divided the population into "good tolerance" and low tolerance at KG = 1.5. Units of KG: min−1.
FiGURE 2 Frequency histogram of the KG values of the 18 subjects under study, calculated from the IVGTT. Because no KG values were found between 1.4 and 1.8, we arbitrarily divided the population into "good tolerance" and low tolerance at KG = 1.5. Units of KG: min−1.From the PDF
FIGURE 3 IVGTT results for four groups of subjects: lean, good tolerance (group I), lean lower tolerance (group II), obese, good tolerance (group III), obese, lower tolerance (group IV). In all cases, good tolerance implied KG > 1.5; lower tolerance, KG < 1.5. Glucose (330 mg/kg) was injected over 1 min starting at t = 0. Vertical bars represent SEM.
FIGURE 3 IVGTT results for four groups of subjects: lean, good tolerance (group I), lean lower tolerance (group II), obese, good tolerance (group III), obese, lower tolerance (group IV). In all cases, good tolerance implied KG > 1.5; lower tolerance, KG < 1.5. Glucose (330 mg/kg) was injected over 1 min starting at t = 0. Vertical bars represent SEM.From the PDF
FiGURE 4 Ability of the minimal models to describe glucose and insulin kinetics during the IVGTT (examples). Insulin and glucose data are represented by open (O) and filled () circles. Prediction of the insulin kinetics model are the solid curves; upper panels. Glucose kinetics model predicts the time-course of plasma glucose (solid curves, lower panels) as well as the timecourse of "insulin action" (dashed line upper panels; remote insulin [X] in the model of Fig. la).
FiGURE 4 Ability of the minimal models to describe glucose and insulin kinetics during the IVGTT (examples). Insulin and glucose data are represented by open (O) and filled () circles. Prediction of the insulin kinetics model are the solid curves; upper panels. Glucose kinetics model predicts the time-course of plasma glucose (solid curves, lower panels) as well as the timecourse of "insulin action" (dashed line upper panels; remote insulin [X] in the model of Fig. la).From the PDF
FIGURE 5 Relationship between pancreatic responsiveness (φ2; second phase) and S, in all subjects: groups I (), II (O), III (▲), and IV (∆). Top: subjects are segregated according to the S·φ2 product. Bottom: subjects represented on the S1 vs. φ2 plot. The solid line represents φ2·S1 = 75; this "toleranr o , ss on from the "poor" tolerance region.
FIGURE 5 Relationship between pancreatic responsiveness (φ2; second phase) and S, in all subjects: groups I (), II (O), III (▲), and IV (∆). Top: subjects are segregated according to the S·φ2 product. Bottom: subjects represented on the S1 vs. φ2 plot. The solid line represents φ2·S1 = 75; this "toleranr o , ss on from the "poor" tolerance region.From the PDF
FIGURE 6 Dependence of KG upon φ1 in subjects from groups I, II, and III (upper line, n = 11, S1 = 5.1 ±0.7 min−½μU per ml) and group IV (lower line, n = 7, S1 = 2.0±0.4 min−¹½µU per ml). Insulin resistance was characteristic of group IV, but not I, II and III (Table III). Slopes of the two lines are significantly different (P < 0.01).
FIGURE 6 Dependence of KG upon φ1 in subjects from groups I, II, and III (upper line, n = 11, S1 = 5.1 ±0.7 min−½μU per ml) and group IV (lower line, n = 7, S1 = 2.0±0.4 min−¹½µU per ml). Insulin resistance was characteristic of group IV, but not I, II and III (Table III). Slopes of the two lines are significantly different (P < 0.01).From the PDF
FIGURE 7 Relationship between S and basal insulin in all patients studied. Basal insulin is significantly correlated with S1 when insulin resistance is manifest (S1 < 3.0; r = 0.65) but not in the sensitivity range 3.0–9.6 (r = 0.08).
FIGURE 7 Relationship between S and basal insulin in all patients studied. Basal insulin is significantly correlated with S1 when insulin resistance is manifest (S1 < 3.0; r = 0.65) but not in the sensitivity range 3.0–9.6 (r = 0.08).From the PDF

Verification

Claims the paper makes

2 Valid · 0 Not valid · 4 Not checked · 44 Own results and interpretations

27 more claims

Create a free account to see all 50 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 14
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Research works printed but not linked: 2

  1. [18]18. Goodwin, C., and R. L. Payne. 1977. Dynamic System Identification. Academic Press, Inc., New York.
  2. [14]14. Bergman, R. N., C. R. Bowden, and C. Cobelli. 1981. The minimal model approach to quantification of factors controlling glucose disposal in man. In Carbohydrate Metabolism: Quantitative Physiology and Mathematical Modeling. C. Cobelli, and R. Bergman, editors. John Wiley & Sons, Inc., London. 269–296.

Cited by

See all 1,647

Metadata

Authors
Bergman, R. N., Phillips, L. S., & Cobelli, C.
Affiliations
Northwestern University (US)
Venue
Journal of Clinical Investigation
Published
1981-12-01
Volume
68
Issue
6
Pages
1456-1467
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2156353972
Cited by
1,640
References
30
Citations by year
2026: 32 · 2025: 38 · 2024: 44 · 2023: 31 · 2022: 45 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 66 · 2017: 66 · 2016: 59 · 2015: 63 · 2014: 60 · 2013: 59 · 2012: 73
FWCI
3.42
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Northwestern University
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK029867)
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucose tolerance, insulin sensitivity, beta-cell glucose sensitivity, insulin resistance, pancreatic insufficiency, intravenous glucose tolerance test, first-phase insulin response, second-phase insulin response, obesity, impaired glucose tolerance, insulin kinetics, glucose kinetics
MeSH terms
Body Weight, Female, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Kinetics, Male, Models, Biological, Obesity, Pancreas

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.